Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire•06/08/2026•08:00 ET
0
Whiz Insights
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 --
-- Favorable arbitration resolution with Beam Therapeutics affirms Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency; IND and/or CTA submission expected in 3Q 2026, with initial clinical data in 2027 --
Get started
Create a free account to read the full story.